BioVie (BIVI) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed BioVie (BIVI) over the past year, gaining 451.9% versus a loss of 35.0%. Over five years, GTBP leads with a -96.7% price change compared with -99.8% for BIVI. BioVie is the larger company by market cap ($12.1 million vs $12.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIVI | GTBP |
|---|---|---|
| Share price | $1.39 | $6.68 |
| Market cap | $12.07M | $12.05M |
| 1-day change | +8.59% | +12.27% |
| YTD return | +10.34% | +659.24% |
| 1-year return | -35.03% | +451.85% |
| 5-year return | -99.78% | -96.72% |
| EPS (TTM) | $-3.05 | $-147.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.79 | $28.75 |
| 52-week low | $0.82 | $4.91 |
| Distance from 52-week high | -63.32% | -76.77% |
| Analyst consensus | none | none |
| Avg. price target upside | +278.42% | +1022.75% |
| Average volume | 4.60M | 55.52K |
| Shares outstanding | 8.68M | 1.80M |
| Employees | 13 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed BIVI by 486.9 percentage points over the past year.
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
BIVI vs GTBP FAQ
Which is bigger, BioVie or GT Biopharma?
BioVie (BIVI) is larger, with a market capitalization of $12.07M compared with $12.05M for GT Biopharma (GTBP).
Which stock has performed better over the past year, BIVI or GTBP?
GTBP returned +451.85% over the past 12 months, compared with -35.03% for BIVI (price return, excluding dividends). Past performance does not predict future results.
Are BioVie and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.